Calmodulin-dependent and -independent Activation of
Endothelial Nitric-oxide Synthase by Heat Shock Protein 90*
Satoru
Takahashi and
Michael E.
Mendelsohn
From the Molecular Cardiology Research Institute, Department of
Medicine and Division of Cardiology, New England Medical Center
Hospitals and Tufts University School of Medicine,
Boston, Massachusetts 02111
Received for publication, December 11, 2002
 |
ABSTRACT |
Endothelial nitric oxide synthase (eNOS), which
generates the endogenous vasodilator, nitric oxide (NO), is highly
regulated by post-translational modifications and protein interactions. Heat shock protein 90 (HSP90) binds directly to eNOS, augmenting NO
production. We have used purified proteins to characterize further the
mechanism by which HSP90 increases eNOS activity at low (100 nM) and high (10 µM) Ca2+
levels. In the presence of calmodulin (CaM), HSP90 increased eNOS
activity dose dependently at both low and high Ca2+
concentrations. This effect was abolished by the specific HSP90 inhibitor geldanamycin (GA) at both calcium concentrations. The EC50 values of eNOS for both Ca2+ and CaM were
decreased in the presence of HSP90. HSP90 also significantly increased
the rate of NADPH-dependent cytochrome c
reduction by eNOS at both low and high Ca2+ concentrations.
HSP90 bound to eNOS in a dose-dependent manner, and the
amount of bound HSP90 also increased with increasing
Ca2+/CaM. At 100 nM Ca2+, HSP90
promoted dose-dependent CaM binding to eNOS that was fully inhibitable by GA. At high calcium, HSP90 did not affect CaM binding to
eNOS, but GA inhibited HSP90 binding to eNOS. At high Ca2+,
HSP90 caused the Vmax of eNOS for
L-arginine to increase by 2-fold, but the
Km of eNOS was unchanged. HSP90 bound preferentially to CaM-prebound eNOS and significantly increased both
its NO synthesis and reductase activities. These data support that
HSP90 promotes eNOS activity by two mechanisms: (i) a
CaM-dependent mechanism operative at low Ca2+
concentrations, characterized by an increase in the affinity of eNOS
for CaM and (ii) a CaM-independent mechanism apparent at high
Ca2+ concentrations, characterized by stimulation of eNOS
reductase activity without further change in CaM binding. These studies contribute to our understanding of eNOS activation by HSP90 and provide
a basis for in vitro studies of other eNOS-interacting proteins.
 |
INTRODUCTION |
Nitric oxide (NO)1 plays
a central role in the maintenance of cardiovascular homeostasis with
effects on blood pressure, angiogenesis, vascular remodeling, and
platelet aggregation (1). Endothelial NO synthase (eNOS), the highly
regulated enzyme responsible for physiological production of NO in the
vasculature, is primarily a Ca2+/calmodulin
(CaM)-dependent enzyme. However, recent studies have revealed additional regulation of eNOS activity by subcellular localization, post-translational modification such as phosphorylation and dephosphorylation, and interactions with several regulatory proteins, including heat shock protein 90 (HSP90) (2-4).
HSP90 increases the activity of eNOS in vitro, and
stimulation of endothelial cells with various stimuli such as vascular endothelial growth factor, histamine, estrogen, and fluid shear stress increases an association of HSP90 with eNOS, resulting in
elevation of NO production (4-6). HSP90 has no effect on eNOS dissociation from caveolin in the absence of Ca2+/CaM but
facilitates CaM-induced eNOS release from eNOS-caveolin (7). Recently,
the domains of eNOS and HSP90 necessary for their interaction were
identified (8, 9). Brouet et al. (6) showed that HSP90
association with eNOS is a prerequisite for subsequent Akt-mediated
stimulation of eNOS. Together with the data that HSP90 directly
interacts with Akt (10), their results suggest that HSP90 might be a
scaffold factor between eNOS and Akt. Accumulating data have indicated
that HSP90 plays a crucial role in regulating eNOS activity in
endothelial cells. However, the mechanism by which HSP90 directly
promotes eNOS activity has remained unclear.
Many studies have suggested the existence of so-called
"Ca2+-independent" activation of eNOS, although it is
well established that Ca2+-activated CaM is necessary for
eNOS activity (11, 12). It was reported that fluid shear stress and
estrogen increase NO production without mobilizing cytosolic
Ca2+ in endothelial cells (13-15) and that HSP90 might
mediate their effects on eNOS (4, 5). As observed in eNOS
phosphorylated by protein kinases such as Akt (at Ser-1177 and -1179 for human and bovine eNOS, respectively) (16-18), these results raised
the possibility that HSP90 also participates in
Ca2+-independent activation of eNOS. Whether
Ca2+-independent activation of eNOS can be induced by HSP90
is also a critical question that needs to be addressed. Therefore, the present study was designated to clarify the mechanism of the
stimulatory effect of HSP90 on eNOS activity including
Ca2+/CaM requirement.
 |
EXPERIMENTAL PROCEDURES |
Materials--
The enzymes, antibodies, and reagents used in
this study and their sources are as follows: bovine brain HSP90, CHAPS,
Dowex AG50WX8, tetrahydrobiopterin, NADPH, FAD, FMN,
L-NAME, L-arginine, cytochrome c,
and superoxide dismutase (SOD) (Sigma); recombinant chicken CaM,
geldanamycin (GA), and protease inhibitor mixture set III (Calbiochem,
La Jolla, CA); anti-eNOS antibody N30020 (BD Transduction Laboratories,
Lexington, KY); anti-HSP90 antibody SPA830, (Stressgen, Victoria, BC);
anti-CaM antibody and protein G-agarose beads (Upstate Biotechnology,
Lake Placid, NY); secondary antibodies linked to horseradish
peroxidase, ECL Western blotting detection reagents,
2',5'-ADP-Sepharose 4B, CaM-Sepharose 4B, and HiTrap Q (Amersham
Biosciences); Bradford protein assay kit (Bio-Rad, Hercules, CA); BENCH
MARK prestained protein ladder (Invitrogen); polyvinylidene difluoride
transfer membrane Immobilon-P (Millipore, Bedford, MA); calcium
calibration buffer kit (Molecular Probes, Eugene, OR);
L-[2,3,4-3H]arginine (45-70 Ci/mmol;
PerkinElmer Life Sciences). HSP90 was reconstituted in 20 mM Tris-HCl (pH 7.5), 10 µM ATP, and 1 mM MgCl2. All other chemicals were of reagent grade.
eNOS Purification--
Recombinant bovine wild-type eNOS,
expressed in Sf9 cells, was purified from the lysate by
sequential chromatography on 2',5'-ADP-Sepharose and CaM according to
the method of List et al. (19). The eNOS was further
purified by HiTrap Q chromatography with a linear gradient of 0.1-1
M NaCl. The eNOS protein was stored at
80 °C in 50 mM Tris-HCl (pH 7.5) buffer containing 1% CHAPS, 1 mM dithiothreitol, 100 mM NaCl, and 5 mM EGTA. Protein concentration was determined with bovine
serum albumin as a standard. In the case of preparing CaM-bound eNOS,
purified eNOS was incubated with 1 mM Ca2+ and
300 nM CaM on ice for 30 min and then loaded to a
2',5'-ADP-Sepharose column. Following washes, CaM-bound eNOS was eluted
with 10 mM NADPH.
NOS Activity Assay--
NOS activity was measured as the
conversion of L-[3H]arginine to
L-[3H]citrulline as described by Bredt and
Snyder (20). Free calcium concentrations were calculated at pH 7.5 and
100 mM NaCl with KD
(Ca2+-EGTA) of 27.9 nM at 37 °C, and the
desired concentrations were achieved by mixing EGTA and
Ca2+-EGTA (21). eNOS (9.8 nM) was preincubated
with HSP90 at room temperature for 5 min, because the 5-min treatment
reached the maximal effect of HSP90 (data not shown). In some
experiments, HSP90 was treated with 1 µM GA. eNOS was
then mixed with the reaction buffer consisting of 25 mM
Tris-HCl (pH 7.5), 5 mM CHAPS, 100 mM NaCl, 1 mM dithiothreitol, 1 mM NADPH, 20 µM FAD, 20 µM FMN, 20 µM
tetrahydrobiopterin, and 300 nM CaM in the presence of EGTA or Ca2+. NOS reaction was initiated by adding 100 µM L-[3H]arginine (1 µCi),
and incubation was done at 37 °C for 10 min unless otherwise
stated. The reaction was terminated by adding 50 mM
HEPES-NaOH (pH 5.5) buffer containing 2 mM EGTA and 2 mM EDTA. L-[3H]citrulline was
separated through a Dowex AG50WX8 (Na+-form) column and
then counted on a liquid scintillation analyzer. L-NAME-inhibitable activity was determined as specific eNOS activity.
NADPH Cytochrome c Reductase Activity Assay--
Cytochrome
c reductase activity was determined photometrically
according to previously reported methods (22) with minor modifications.
eNOS (9.8 nM) was mixed with HSP90 (45 nM) in
the presence of EGTA or Ca2+ in reaction buffer consisting
of 50 mM HEPES-NaOH (pH 7.5), 100 mM NaCl, 0.5 mM CHAPS, 200 µM cytochrome c, and
300 nM CaM. SOD was added at 1 unit. The reductase reaction
was initiated by adding 100 µM NADPH, and then change in
absorbance at 550 nm was measured at 23 °C for 3 min. The rate of
reduction was calculated using an extinction coefficient of 0.021 µM
1 cm
1 for cytochrome
c at 550 nm.
Immunoprecipitation and Immunoblotting of eNOS, HSP90, and
CaM--
eNOS (9.8 nM) was incubated at 37 °C for 10 min in the NOS reaction buffer in the presence of EGTA or
Ca2+ after eNOS was preincubated with HSP90 at room
temperature for 5 min. eNOS complex was then immunoprecipitated by
anti-eNOS antibody (1:100-200) and successively by protein G-agarose
beads at 4 °C. Following washes with the corresponding buffer, the
immunoprecipitates were suspended in sample buffer, separated by
SDS-PAGE, and transferred onto polyvinylidene difluoride membranes. The
blots were incubated with the primary antibody against eNOS (1:1000),
HSP90 (1:1000), or CaM (1:500) and then probed with the secondary
antibody linked to peroxidase. Immunoreactive proteins were visualized
on x-ray films with chemiluminescent ECL reagents. The intensity of
each band was measured by a densitometer and normalized to the
corresponding eNOS. Relative intensity to the defined group as
described in each figure legend was calculated.
Statistical Analyses--
Data are presented as means ± S.E. Statistical differences were evaluated by Student's t
test. EC50, Km and
Vmax values were obtained from the direct fits
to the data according to Hill equation on SigmaPlot 2001 software.
p value of <0.05 was regarded as significant.
 |
RESULTS |
HSP90 Increases eNOS Activity in a Calcium- and
CaM-dependent Manner--
Recombinant bovine eNOS was
purified to near homogeneity by sequential chromatographic steps (Fig.
1A, inset). The
protein in our preparation was recognized by anti-eNOS antibody, but
immunoblotting of the preparation with anti-HSP90 and anti-CaM
antibodies were both negative (data not shown). We examined the effects
of HSP90 on eNOS activity in the presence of CaM at several calcium
concentrations (Fig. 1A). Depletion of free Ca2+
(<1 nM) was achieved by addition of 10 mM EGTA
to the reaction. eNOS activity was negligible under these conditions,
and HSP90 was unable to stimulate eNOS activity in the presence of
EGTA. Presence of low (100 nM) or high (10 µM) Ca2+ caused activation of eNOS (2.2 ± 0.4 and 13.6 ± 0.6 nmol/min/nmol of protein at 100 nM and 10 µM Ca2+, respectively),
which was in both cases significant in comparison to the
Ca2+-free control. HSP90 also significantly augmented eNOS
activity under both low and high calcium conditions. The increases in
eNOS activity at 100 nM and 10 µM
Ca2+ due to HSP90 were 7.2- and 2.3-fold, respectively,
compared with the corresponding HSP90-free control. GA, a relatively
specific inhibitor of HSP90, had no effect on
Ca2+-activated eNOS activity by itself but completely
inhibited the eNOS-stimulatory effects of HSP90 at both low and high
calcium concentrations. The eNOS reactions at low and high calcium
concentrations proceeded linearly up to 20 min both in the absence and
presence of HSP90 (Fig. 1B), supporting that eNOS in the
absence of HSP90 is not denatured and that the HSP90 effect is likely
due to actions other than protection against thermal denaturation.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 1.
Effect of HSP90 on eNOS activity.
A, eNOS (9.8 nM) was incubated with vehicle
(open columns) or HSP90 (45 nM, closed
columns) in the presence of 300 nM CaM and either 10 mM EGTA, 100 nM Ca2+, or 10 µM Ca2+. GA was added at 1 µM.
eNOS activity was determined at 37 °C for 10 min. Inset,
Coomassie Blue stain of purified eNOS resolved on 10% SDS-PAGE.
Molecular sizes (kDa) of protein markers are 177, 114, 81, 64, 50, 37, 26, and 20. B, eNOS (9.8 nM) was incubated with
vehicle (control) or HSP90 (45 nM) in the presence of 300 nM CaM and either 100 nM or 10 µM
Ca2+, and eNOS activity then was determined at the
indicated times. Data are presented as mean ± S.E. for four and
three determinations for A and B, respectively.
Bold asterisk, light asterisk, and number
sign, significantly different from the control at 10 mM EGTA, the corresponding control, and HSP90-stimulated
activity, respectively.
|
|
HSP90 promoted an increase in Ca2+-activated eNOS activity
in a dose-dependent fashion (Fig.
2). The absolute activity of eNOS was
greater in the presence of 10 µM Ca2+ than
100 nM Ca2+ (Fig. 1A). The overall
stimulation of eNOS was substantially greater over a range of HSP90
concentrations in the presence of 100 nM Ca2+
(~7-fold) than in the presence of 10 µM
Ca2+ (~2-fold). At 100 nM Ca2+,
eNOS activity was 353% above control at 12 nM HSP90 and
697% above control at 45 nM HSP90. At maximal calcium
levels (10 µM Ca2+), the increase in eNOS
activity to increasing HSP90 was smaller (139% at 12 nM
HSP90 and 254% at 45 nM HSP90) but was significant. This
increase occurred with eNOS bound to maximal and constant amounts of
Ca2+/CaM at both of these HSP90 concentrations (see Fig. 5
and results below).

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 2.
Dose response of HSP90 effect on eNOS
activity. eNOS (9.8 nM) was incubated with vehicle
(control) or the indicated dose of HSP90 in the presence of 300 nM CaM and either 100 nM or 10 µM
Ca2+, and then eNOS activity was determined at 37 °C for
10 min. The activity without HSP90 was 2.4 nmol/min/nmol of protein at
100 nM Ca2+ and 14.1 nmol/min/nmol of protein
at 10 µM Ca2+. Data are presented as
mean ± S.E. for four determinations. *, significantly different
from the corresponding control.
|
|
Effect of HSP90 on the EC50 Values of eNOS for
Ca2+ and CaM and Maximal eNOS
Activity--
Ca2+ and CaM dependencies of eNOS
activity were separately examined in the absence and presence of HSP90
(Fig. 3). eNOS activity in the presence
of 300 nM CaM increased in a
Ca2+-dependent manner in the absence and
presence of HSP90 within the range of 30-1000 nM
Ca2+ and was maximally stimulated at calcium concentrations
1 µM (Fig. 3A). HSP90 enhanced the
Ca2+ sensitivity of eNOS under these conditions. The
EC50 values of eNOS for
Ca2+-dependent stimulation were 239 nM and 83 nM in the absence and presence of
HSP90, respectively. HSP90 significantly increased eNOS activity at all
calcium concentrations (maximal increase from 14.9 to 32.4 nmol/min/nmol of protein at 10 µM Ca2+). Fig.
3A shows that the maximal eNOS activity in the presence of
HSP90 and 100 nM Ca2+ was 17.4 nmol/min/nmol of
protein. In the absence of HSP90, the maximal eNOS activity attained
was 14.9 nmol/min/nmol of protein. Therefore, at least 14% of the
maximal measurable eNOS activity in these studies is due to an effect
of HSP90 on the enzyme that is independent of Ca2+/CaM (see
"Discussion").

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 3.
Dose responses of Ca2+ and CaM on
HSP90-increased eNOS Activity. eNOS (9.8 nM) was
incubated with vehicle (control) or HSP90 (45 nM) in the
presence of the varying concentrations of Ca2+ and 300 nM CaM (A) or in the presence of 10 µM Ca2+ and the varying concentrations of CaM
(B), and eNOS activity was measured at 37 °C for 10 min.
Data are presented as mean ± S.E. for four determinations. *,
significantly different from the corresponding control.
|
|
HSP90 also augmented CaM-dependent eNOS activity (Fig.
3B). HSP90 reduced the EC50 value for CaM from
8.5 to 2.7 nM in the presence of 10 µM
Ca2+. The CaM effect became apparent at CaM levels
1
nM, though HSP90 had no measurable effect on eNOS activity
at lower CaM concentrations, even at maximal Ca2+ levels
(Fig. 3B and data not shown).
HSP90 Increases NADPH Cytochrome c Reductase Activity of eNOS in a
Calcium- and CaM-dependent Manner--
The rate of NO
synthesis by eNOS is determined by the intrinsic activity of the
reductase domain of the enzyme to transfer electrons to heme (22-24).
We examined whether the increase in eNOS activity in the presence of
HSP90 is accompanied by enhanced reductase activity of eNOS by
measuring NADPH-dependent cytochrome c reduction
in the presence of 300 nM CaM. In the presence of EGTA,
cytochrome c reductase activity of eNOS was minimal, and HSP90 had no effect on this activity (Fig.
4A). In the presence of 100 nM or 10 µM Ca2+, reductase
activity was elevated in a Ca2+-dependent
manner (0.22 ± 0.03 versus 1.0 ± 0.1 µ mol/min/mol of eNOS protein). The Ca2+/CaM-activated
reductase activity was significantly enhanced by HSP90 at both 100 nM and 10 µM Ca2+ (5.9- and
1.8-fold, respectively). Next, we repeated these studies in the
presence of SOD to explore differences that might have occurred due to
reduction of cytochrome c by eNOS-derived superoxide (22)
(Fig. 4B). SOD decreased the rate of cytochrome c
reduction somewhat for control eNOS both at 100 nM and 10 µM Ca2+ (28.1% and 25.7%, respectively),
but the majority of Ca2+/CaM-dependent
reductase activity was still present. The extent of uncoupling was
quite similar to previously reported values determined by the same
method (22). The cytochrome c reductase activity of eNOS in
the presence of HSP90 was only slightly reduced by SOD, (6.7% at 100 nM Ca2+ and 10.3% at 10 µM
Ca2+) compared with the corresponding value without SOD.
HSP90 still significantly promoted cytochrome c reductase
activity of eNOS in the presence of SOD to degrees similar to those
measured in the absence of SOD (7.3- and 2.0-fold at 100 nM
and 10 µM Ca2+, respectively). The extents of
the increases in eNOS activity (Fig. 1A) and reductase
activities (Fig. 4) in the presence of HSP90 were thus of similar
magnitudes. These data support that HSP90 primarily stimulates the
reductase activity of eNOS and, to a much lesser extent, inhibits
uncoupling of the enzyme.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 4.
Effect of HSP90 on cytochrome c
reductase activity of eNOS. eNOS (9.8 nM) was
incubated with vehicle (control) or HSP90 (45 nM) in the
presence of 300 nM CaM and either 10 mM EGTA,
100 nM Ca2+, or 10 µM
Ca2+, and then NADPH-dependent cytochrome
c reductase activity was determined at 23 °C for 3 min in
the absence (A) or presence (B) of SOD. Data are
presented as mean ± S.E. for four determinations. *,
significantly different from the corresponding control.
|
|
HSP90 and CaM Cooperatively Potentiate Their Binding to
eNOS--
Binding of HSP90 and CaM to eNOS was examined by
immunoprecipitation studies with anti-eNOS antibody (Fig.
5). HSP90 bound to eNOS in the absence of
Ca2+ to a small degree, but eNOS-HSP90 complex formation
was enhanced in a Ca2+-dependent manner. eNOS
bound more HSP90 as the concentration of HSP90 present was increased.
CaM was detected in the eNOS immunopellet only in the presence of
Ca2+. At 100 nM Ca2+, HSP90 dose
dependently increased the amount of CaM bound to eNOS along with the
corresponding increase in HSP90 bound to the synthase. The absolute
amount of CaM bound in the presence of 100 nM
Ca2+ and 45 nM HSP90 was substantially lower
than the amount of CaM bound to eNOS at 10 µM
Ca2+ even in the absence of HSP90. The level of eNOS
activity at 100 nM Ca2+ due to the presence of
HSP90 was higher than the control eNOS activity at 10 µM
Ca2+ (Fig. 1A). In contrast, HSP90 had no
further effect on CaM binding at 10 µM Ca2+,
although HSP90 still significantly (though modestly) increased eNOS
activity (cf. Figs. 1A and 2). GA potently
inhibited HSP90 binding to eNOS in the absence and presence of calcium
and abolished the effect of HSP90 on CaM binding at 100 nM.
However, CaM binding to eNOS at 10 µM Ca2+
was not affected by GA. The amount of CaM bound to eNOS at 10 µM Ca2+ was not influenced by HSP90 or GA,
indicating that Ca2+/CaM binding to eNOS is saturated at 10 µM Ca2+.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 5.
Binding of HSP90 and CaM to eNOS. eNOS
(9.8 nM) was incubated at 37 °C for 10 min with the
indicated dose of HSP90 in the presence of 300 nM CaM and
either 10 mM EGTA, 100 nM Ca2+, or
10 µM Ca2+. GA treatment was performed at 1 µM. Thereafter, eNOS was recovered by immunoprecipitation
with anti-eNOS antibody, and the presence of eNOS, HSP90, and CaM was
evaluated by immunoblotting. Ratios of intensity of HSP90 and CaM to
eNOS in each group were determined, and then each relative intensity
was calculated. Data are expressed as % of 45 nM HSP90 and
10 µM Ca2+ group and presented as mean ± S.E. for four determinations.
|
|
CaM-independent Effects of HSP90 on eNOS--
At 10 µM Ca2+, HSP90 increased both the NO synthase
and cytochrome c reductase activities of eNOS. A
dose-dependent increase in HSP90 binding to eNOS also was
observed at high Ca2+ concentration. However, CaM binding
was unchanged by HSP90 at this calcium concentration. To further
explore the HSP90 effects at 10 µM Ca2+, we
compared eNOS activities and measured the Vmax
and Km values of eNOS for L-arginine at
10 µM Ca2+ in the absence and presence of
HSP90 (Fig. 6). eNOS exhibited a higher
velocity of NO synthesis in the presence of HSP90. The Vmax value for arginine was increased 2-fold by
HSP90 (from 14.6 ± 0.15 to 28.7 ± 4.2 nmol/min/nmol of
protein for eNOS in the absence or presence of HSP90, respectively).
However, HSP90 did not affect the affinity for L-arginine
as the Km value for L-arginine was
4.2 ± 0.3 in the presence and 4.1 ± 0.2 µM in
the absence of HSP90.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 6.
Michaelis-Menten analysis of eNOS with HSP90
at 10 µM Ca2+.
eNOS (9.8 nM) was incubated with vehicle (control) or HSP90
(45 nM) in the presence of 10 µM
Ca2+ and 300 nM CaM, and then eNOS activity was
determined as a function of L-arginine concentration. Data
are presented as mean ± S.E. for three determinations.
|
|
We prepared eNOS in the presence of EGTA (CaM-free eNOS) or 1 mM Ca2+ (CaM-bound eNOS) (Fig.
7A) and examined the effects
of HSP90 on both the synthase and reductase activities of the enzyme
(Fig. 7, B and C). HSP90 bound preferentially to
CaM-bound eNOS and GA treatment prevented binding of HSP90 to eNOS. In
addition, both NOS and cytochrome c reductase activities of
CaM-bound eNOS were significantly enhanced by HSP90. These results show
that HSP90 has a direct effect on eNOS pre-bound to CaM even in the absence of added (exogenous) CaM.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 7.
Effects of HSP90 on the CaM-prebound form of
eNOS. A, Ca2+/CaM-free (in 10 mM EGTA) and CaM-bound eNOS (in 1 mM
Ca2+) were subjected to immunoblot analyses with anti-eNOS
and anti-CaM antibodies. B and C, CaM-free or
CaM-bound eNOS (9.8 nM) was incubated at 37 °C for 10 min with vehicle or HSP90 (45 nM) in the presence of 10 mM EGTA or 1 mM Ca2+, respectively.
Note that free CaM was not added exogenously. GA treatment was
performed at 1 µM. B, thereafter, eNOS was
recovered by immunoprecipitation with anti-eNOS antibody, and the
presence of eNOS and HSP90 was evaluated by immunoblotting. Ratio of
intensity of HSP90 to eNOS in each group was determined, and then each
relative intensity was calculated. Data are expressed as percentage of
CaM-free eNOS activity in the presence of HSP90. C, eNOS and
cytochrome c activities are shown as a percentage of
CaM-bound eNOS activity in the absence of HSP90. Open and
closed columns represent control and HSP90 group,
respectively. Data are mean ± S.E. for four determinations. * and
#, significantly different from control.
|
|
 |
DISCUSSION |
We have examined the mechanism of HSP90 activation of eNOS
in vitro. HSP90 appears to increase eNOS activity in the
presence of Ca2+ and CaM by two mechanisms. Under
conditions where eNOS is not saturated with CaM, HSP90 reduced the
EC50 values for Ca2+ and CaM and dose
dependently increased the amount of CaM bound to eNOS. These results
indicate that HSP90 elevates the binding affinity of eNOS for CaM,
resulting in an increase in NO synthesis. Gratton et al. (7)
reported previously that CaM-induced dissociation of eNOS from caveolin
is facilitated by HSP90 through an unknown mechanism. Our results
support that an HSP90-induced increase in CaM binding might facilitate
eNOS dissociation from this protein. The CaM-dependent
mechanism we observed appears similar to the effect of HSP90 on nNOS,
though the effect of HSP90 on eNOS activity appears to be greater than
its effect on nNOS (25).
Our data support that HSP90 also activates eNOS by a CaM-independent
mechanism, which was detectable at high calcium levels. The evidence
for a CaM-independent HSP90 effect includes the following. (i) HSP90
dose dependently increased NO synthesis and reductase activities of
eNOS in the presence of saturating levels of Ca2+ and CaM
(Figs. 2-4). (ii) HSP90 binding to eNOS increases when the quantity of
CaM bound to eNOS remains constant (Fig. 5), and this results in a
further increase in eNOS activity (from 139% to 254% of basal eNOS
activity at 12 and 45 nM HSP90, respectively; Fig. 2).
(iii) Despite the fact that CaM is a critical determinant of
Km, HSP90 significantly increased the
Vmax for L-arginine without
affecting the Km in the presence of saturating Ca2+ and CaM (Fig. 6). (iv) HSP90 association with
CaM-bound eNOS results in increases in NO synthesis and reductase
activities of eNOS even in the absence of added CaM or any change in
CaM binding to eNOS (Fig. 7). (v) These effects of HSP90 were prevented by an HSP90-specific inhibitor, geldanamycin (Figs. 1, 5, and 7). The
CaM-independent effect of HSP90 causes only an ~2-fold increase in
eNOS activity at 45 nM HSP90 and is therefore weaker than
the CaM-dependent effect of HSP90 on eNOS activity under these conditions. However, the combined CaM-dependent and
-independent effects of HSP90 may both be active to varying degrees
across a range of Ca2+ concentrations and cooperate in an
additive or synergistic fashion to stimulate eNOS activity. Pritchard
et al. (27) reported that HSP90 may prevent eNOS uncoupling
and thus both inhibit superoxide production and increase NO synthesis.
We observed modest eNOS uncoupling in the absence of HSP90, consistent
with this prior work (27). However, uncoupling accounted for at most
20-25% of the decrease in the eNOS cytochrome c reductase,
supporting that the stimulatory effects of HSP90 on eNOS activity
account for the majority of the HSP90 effect.
The data here support that HSP90 and CaM bind cooperatively to eNOS.
eNOS has a higher affinity for CaM in the presence of HSP90, and,
conversely, CaM-activated eNOS has a higher affinity for HSP90.
Increases in both binding affinities might be expected to stabilize a
complex between eNOS with CaM and HSP90. The precise molecular
mechanisms by which HSP90 activates eNOS remain to be determined, but a
refined model can be proposed based in part on the biological roles of
HSP90 in other systems. HSP90 acts as a molecular chaperone
and is involved in protein folding and regulation of protein
conformation in signaling pathways such as those involving steroid
hormone receptors and protein kinases (26). It is plausible that HSP90
induces a conformational change in eNOS that results in increases in
the affinity of eNOS for CaM (CaM-dependent mechanism) and
in increased reductase activity (CaM-independent mechanism). The
CaM-independent effect of HSP90 to enhance reductase activity is
consistent with the established concept that the rate of NO synthesis
by eNOS is determined by this intrinsic reductase activity
(22-24).
The present study demonstrates that HSP90 leads to relatively large
increases in eNOS nitric oxide production at physiological Ca2+ concentrations. In concert with Akt phosphorylation,
this may account for a marked reduction in the need for
Ca2+ to achieve a given level of eNOS activation (6). This
may be one explanation for observed increases in NO production by stimuli such as fluid shear stress and estrogen in the absence of
detectable increases in cytosolic Ca2+ (5, 14, 28-30). In
conclusion, HSP90 promotes eNOS activity by CaM-dependent
and CaM-independent mechanisms, increases the affinity of eNOS for CaM,
and stimulates an increase in the intrinsic reductase activity of eNOS
in the presence of a fixed amount of CaM. Since HSP90 and CaM bind to
eNOS at lower Ca2+ levels, both mechanisms of
HSP90-dependent eNOS activation are predicted to contribute
to the increase in efficiency of NO production by eNOS at physiological
Ca2+ concentrations.
 |
FOOTNOTES |
*
This work was supported in part by National Institutes of
Health SCOR in Ischemic Heart Disease P50 HL63494, R01 HL55309, and R01
HL56069 (to M. E. M.). The reported findings are solely the
responsibility of the authors and do not necessarily represent the
official views of the National Institutes of Health.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Tufts University
School of Medicine, New England Medical Center, Molecular Cardiology Research Institute, 750 Washington St., Box 80, Boston, MA 02111. Tel.:
617-636-9370; Fax: 617-636-1444; E-mail:
mmendelsohn@lifespan.org.
Published, JBC Papers in Press, January 7, 2003, DOI 10.1074/jbc.M212651200
 |
ABBREVIATIONS |
The abbreviations used are:
NO, nitric oxide;
NOS, NO synthase;
eNOS, endothelial NOS;
nNOS, neuronal NOS;
HSP, heat
shock protein;
CaM, calmodulin;
L-NAME, NG-nitro-L-arginine methyl ester;
GA, geldanamycin;
SOD, superoxide dismutase;
CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid.
 |
REFERENCES |
1.
|
Ignarro, L. J.,
Cirino, G.,
Casini, A.,
and Napoli, C.
(1999)
J. Cardiovasc. Pharmacol.
34,
879-886[CrossRef][Medline]
[Order article via Infotrieve]
|
2.
|
Govers, R.,
and Rabelink, T. J.
(2001)
Am. J. Physiol.
280,
F193-F206
|
3.
|
Fleming, I.,
and Busse, R.
(1999)
Cardiovasc. Res.
43,
532-541[CrossRef][Medline]
[Order article via Infotrieve]
|
4.
|
Garcia-Cardena, G.,
Fan, R.,
Shah, V.,
Sorrentino, R.,
Cirino, G.,
Papapetropoulos, A.,
and Sessa, W. C.
(1998)
Nature
392,
821-824[CrossRef][Medline]
[Order article via Infotrieve]
|
5.
|
Russell, K. S.,
Haynes, M. P.,
Caulin-Glaser, T.,
Rosneck, J.,
Sessa, W. C.,
and Bender, J. R.
(2000)
J. Biol. Chem.
275,
5026-5030[Abstract/Free Full Text]
|
6.
|
Brouet, A.,
Sonveaux, P.,
Dessy, C.,
Balligand, J.-L.,
and Feron, O.
(2001)
J. Biol. Chem.
276,
32663-32669[Abstract/Free Full Text]
|
7.
|
Gratton, J.-P.,
Fontana, J.,
O'Connor, D. S.,
Garcia-Cardena, G.,
McCabe, T. J.,
and Sessa, W. C.
(2000)
J. Biol. Chem.
275,
22268-22272[Abstract/Free Full Text]
|
8.
|
Harris, M. B.,
Ju, H.,
Venema, V. J.,
Blackstone, M.,
and Venema, R. C.
(2000)
Gen. Pharmacol.
35,
165-170[Medline]
[Order article via Infotrieve]
|
9.
|
Fontana, J.,
Fulton, D.,
Chen, Y.,
Fairchild, T. A.,
McCabe, T. J.,
Fujita, N.,
Tsuruo, T.,
and Sessa, W. C.
(2002)
Circ. Res.
90,
866-873[Abstract/Free Full Text]
|
10.
|
Sato, S.,
Fujita, N.,
and Tsuruo, T.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
10832-10837[Abstract/Free Full Text]
|
11.
|
Forstermann, U.,
Pollock, J. S.,
Schmidt, H. H.,
Heller, M.,
and Murad, F.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
1788-1792[Abstract]
|
12.
|
Busse, R.,
and Mülsch, A.
(1990)
FEBS Lett.
265,
133-136[CrossRef][Medline]
[Order article via Infotrieve]
|
13.
|
Kuchan, M. J.,
and Frangos, J. A.
(1994)
Am. J. Physiol.
266,
C628-C636[Medline]
[Order article via Infotrieve]
|
14.
|
Caulin-Glaser, T.,
Garcia-Cardena, G.,
Sarrel, P.,
Sessa, W. C.,
and Bender, J. R.
(1997)
Circ. Res.
81,
885-892[Abstract/Free Full Text]
|
15.
|
Ayajiki, K.,
Kindermann, M.,
Hecker, M.,
Fleming, I.,
and Busse, R.
(1996)
Circ. Res.
78,
750-758[Abstract/Free Full Text]
|
16.
|
Fulton, D.,
Gratton, J.-P.,
McCabe, T. J.,
Fontana, J.,
Fujio, Y.,
Walsh, K.,
Franke, T. F.,
Papapetropoulos, A.,
and Sessa, W. C.
(1999)
Nature
399,
597-601[CrossRef][Medline]
[Order article via Infotrieve]
|
17.
|
Dimmeler, S.,
Fleming, I.,
Fisslthaler, B.,
Hermann, C.,
Busse, R.,
and Zeiher, A. M.
(1999)
Nature
399,
601-605[CrossRef][Medline]
[Order article via Infotrieve]
|
18.
|
Michell, B. J.,
Griffiths, J. E.,
Mitchelhill, K. I.,
Rodriguez-Crespo, I.,
Tiganis, T.,
Bozinovski, S.,
Ortiz de Montellano, P. R.,
Kemp, B. E.,
and Pearson, R. B.
(1991)
Curr. Biol.
9,
845-848[CrossRef]
|
19.
|
List, B. M.,
Klosch, B.,
Volker, C.,
Gorren, A. C.,
Sessa, W. C.,
Werner, E. R.,
Kukovetz, W. R.,
Schmidt, K.,
and Mayer, B.
(1997)
Biochem. J.
323,
159-165[Medline]
[Order article via Infotrieve]
|
20.
|
Bredt, D. S.,
and Snyder, S. H.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
682-685[Abstract]
|
21.
|
Tsien, R.,
and Pozzan, T.
(1989)
Methods Enzymol.
172,
230-262[Medline]
[Order article via Infotrieve]
|
22.
|
McCabe, T. J.,
Fulton, D.,
Roman, L. J.,
and Sessa, W. C.
(2000)
J. Biol. Chem.
275,
6123-6128[Abstract/Free Full Text]
|
23.
|
Nishida, C. R.,
and Ortiz de Montellano, P. R.
(1998)
J. Biol. Chem.
273,
5566-5571[Abstract/Free Full Text]
|
24.
|
Nishida, C. R.,
and Ortiz de Montellano, P. R.
(1999)
J. Biol. Chem.
274,
14692-14698[Abstract/Free Full Text]
|
25.
|
Song, Y,
Zweier, J. L.,
and Xia, Y.
(2001)
Biochem. J.
355,
357-360[CrossRef][Medline]
[Order article via Infotrieve]
|
26.
|
Pratt, W. B.
(1998)
Proc. Soc. Exp. Biol.
217,
420-434[Abstract]
|
27.
|
Pritchard, K. A., Jr.,
Ackerman, A. W.,
Gross, E. R.,
Stepp, D. W.,
Shi, Y.,
Fontana, J. T.,
Baker, J. E.,
and Sessa, W. C.
(2001)
J. Biol. Chem.
276,
17621-17624[Abstract/Free Full Text]
|
28.
|
Simoncini, T.,
Hafezi-Moghadam, A.,
Brazil, D. P.,
Ley, K.,
Chin, W. W.,
and Liao, J. K.
(2000)
Nature
407,
538-541[CrossRef][Medline]
[Order article via Infotrieve]
|
29.
|
Haynes, M. P.,
Sinha, D.,
Russell, K. S.,
Collinge, M.,
Fulton, D.,
Morales-Ruiz, M.,
Sessa, W. C.,
and Bender, J. R.
(2000)
Circ. Res.
87,
677-682[Abstract/Free Full Text]
|
30.
|
Hisamoto, K.,
Ohmichi, M.,
Kurachi, H.,
Hayakawa, J.,
Kanda, Y.,
Nishio, Y.,
Adachi, K.,
Tasaka, K.,
Miyoshi, E.,
Fujiwara, N.,
Taniguchi, N.,
and Murata, Y.
(2001)
J. Biol. Chem.
276,
3459-3467[Abstract/Free Full Text]
|
Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.